Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biocryst Pharmaceuticals Inc (BCRX) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (131)	5/16/2007 1:06:16 PM
From: tuck	Read Replies (1) \| Respond to of 269

Rick, Do you know if the Shionogi upfront payment has been received? Since the deal was done by March 5th, I would have expected it to be in the bank before the end of the quarter. That would have left BCRX with somewhere around $54 in cash at the end of the quarter. But they only had $43 million. TIA & Cheers, Tuck

To: scaram(o)uche who wrote (131)	10/30/2012 6:43:01 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 269

>> Bugg's great HCV molecule is vapor. But the backups are incredible, trust them. << Six years later and at least eight years after Bugg started his bull....... finance.yahoo.com BioCryst Pharmaceuticals, Inc. (BCRX) today announced the withdrawal of its Investigational New Drug application (IND) for the antiviral nucleoside, BCX5191, following a discussion with the U.S. Food and Drug Administration (FDA). The FDA indicated concerns regarding the preclinical toxicity profile of BCX5191 at exposure levels that they believe are likely to be necessary to reduce viral load in patients infected with the hepatitis C virus (HCV).